论文部分内容阅读
美菲康（盐酸吗啡控释片）是ＷＨＯ推荐的治疗癌痛病人的第三阶梯药物。本文总结１４０例重度癌痛病人服用美菲康的临床疗效、副作用及处理方法。完全缓解７８例（５５．７％），明显缓解３６例（２５．７％），中度缓解２６例（１８．６％），总有效率１００％。发生恶心反应４２例（３０．０％），呕吐反应６例（４．３％），便秘５８例（４１．４５％），轻度头晕１０例（７．１％），尿潴留１６例（１１．４％），副作用均较轻微，经相应处理后多于一周内消退，期间不须停服美菲康，而继续服药后副作用极少再现。文献报道尿潴留较少，本组使用硫酸新斯的明１ｍｇ／次皮下注射后很快缓解，从而避免了常规留置导尿给病人带来的不适和烦恼以及感染机会，作者认为，美菲康是一个持续１２小时的控释口服强效镇痛药物，其疗效可靠，临床使用安全方便，副作用轻微与短暂而且容易克服，极少发生成瘾现象（心理依赖性），是目前治疗癌痛第三阶梯的最好药物。
The United States Feikang (morphine hydrochloride controlled-release tablets) is recommended by the WHO treatment of cancer pain in patients with third-tier drugs. This article summarizes the clinical efficacy, side effects and treatment of 140 cases of patients with severe cancer pain taking pheniconazole. 78 cases (55.7%) were relieved completely, 36 cases (25.7%) were alleviated obviously, 26 cases (18.6%) were relieved moderately, and the total effective rate was 100%. Nausea reaction occurred in 42 cases (30.0%), vomiting reaction in 6 cases (4.3%), constipation in 58 cases (41.45%), mild dizziness in 10 cases (7.1%) and urinary retention in 16 cases 11.4%). All the side effects were mild, after more than one week of treatment, no subsidence was required. Reported in the literature less urinary retention, the group of neostigmine sulfate subcutaneous injection of 1mg / subcutaneous injection soon relieved, thus avoiding the conventional indwelling catheterization to patients with discomfort and worry and infection opportunities, the author believes that the United States Feikang Is a sustained-release oral potent analgesic that lasts for 12 hours. Its efficacy is reliable, its clinical use is safe and convenient, the side effects are mild and transient, and it is easy to overcome. It is a rare occurrence of addiction (psychological dependence) Three steps of the best medicine.